Clinical Sciences & Operations

Trials

Studies that name Clinical Sciences & Operations as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:10 UTC. Showing 200 of 890. Open this list on ClinicalTrials.gov

• Ph4
  NCT07861542 · Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19

  Sanofi · recruiting · COVID-19 · study director
• Ph3
  NCT07484230 · A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

  Sanofi · withdrawn · Chronic Rhinosinusitis With Nasal Polyps · study director
• Ph3
  NCT07424144 · An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps

  Sanofi · active not recruiting · Chronic Rhinosinusitis With Nasal Polyps · study director
• Ph3
  NCT07247188 · Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease

  Sanofi · recruiting · Sickle Cell Disease · study director
• Ph1
  NCT06960395 · Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

  Vir Biotechnology, Inc. · recruiting · Solid Tumor Malignancies, EGFR Positive Solid Tumors, EGFR · study director
• Ph1
  NCT06850051 · A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.

  Sanofi · completed · Healthy Volunteers, Influenza Vaccination, Respiratory Syncytial Virus Vaccination · study director
• Ph3
  NCT06838000 · Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents

  Sanofi Pasteur, a Sanofi Company · active not recruiting · Pneumococcal Infections · study director
• Ph3
  NCT06834347 · A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

  Sanofi · active not recruiting · Chronic Rhinosinusitis With Nasal Polyps · study director
• Ph3
  NCT06834360 · A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

  Sanofi · active not recruiting · Chronic Rhinosinusitis With Nasal Polyps · study director
• N/A
  NCT06793826 · Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea

  Sanofi Pasteur, a Sanofi Company · completed · Hepatitis B, Haemophilus Influenzae Type b Immunisation · study director
• Ph1/Ph2
  NCT06744205 · A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older

  Sanofi Pasteur, a Sanofi Company · completed · Influenza, Healthy Volunteers · study director
• Ph1
  NCT06698198 · Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)

  Sanofi Pasteur, a Sanofi Company · completed · Pneumococcal Immunization · study director
• N/A
  NCT06694025 · Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe.

  Sanofi · not yet recruiting · Immunization, Influenza (Healthy Volunteers) · study director
• N/A
  NCT06695897 · A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany

  Sanofi · recruiting · Eosinophilic Esophagitis · study director
• Ph2
  NCT06691113 · A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps

  Sanofi · completed · Chronic Rhinosinusitis Without Nasal Polyps · study director
• Ph4
  NCT06671587 · iGlarLixi CGM Study in Chinese T2D Individuals After OADs

  Sanofi · recruiting · Type 2 Diabetes (T2D) · study director
• Ph1
  NCT06647069 · A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

  Sanofi · recruiting · Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA) · study director
• Ph4
  NCT06616415 · A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic Therapies

  Sanofi · completed · Chronic Graft Versus Host Disease · study director
• N/A
  NCT06481904 · Registry for Stage 2 Type 1 Diabetes

  Sanofi · recruiting · Type 1 Diabetes · study director
• Ph1
  NCT06444191 · Pharmacokinetics (PK) of Rilzabrutinib (PRN1008) in Healthy Japanese and Caucasian Subjects

  Principia Biopharma, a Sanofi Company · completed · Healthy Volunteers · study director
• Ph1
  NCT06444204 · A Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Single-Dose Pharmacokinetics of Rilzabrutinib (PRN1008)

  Principia Biopharma, a Sanofi Company · completed · Hepatic Function Abnormal, Healthy Volunteers · study director
• N/A
  NCT06415175 · Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain

  Sanofi · active not recruiting · Atopic Dermatitis · study director
• N/A
  NCT06393946 · Study in Adults With Severe Chronic Rhinosinusitis With Nasal Polyposis Treated With Dupilumab in France

  Sanofi · active not recruiting · Chronic Rhinosinusitis With Nasal Polyposis · study director
• Ph1
  NCT06392477 · A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma

  Sanofi · recruiting · B-cell Non Hodgkin Lymphoma · study director
• Ph1
  NCT06284902 · Bioavailability Study of Fexofenadine HCl New Formulation Tablet

  Opella Healthcare Group SAS, a Sanofi Company · completed · Healthy Volunteers · study director
• N/A
  NCT06258057 · Safety of Tetanus, Diphtheria, Acellular Pertussis With 5 Acellular Pertussis Components (Tdap5) Vaccination During Pregnancy

  Sanofi · active not recruiting · Pertussis (Whooping Cough) · study director
• Ph3
  NCT06208306 · A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD

  Sanofi · completed · Chronic Obstructive Pulmonary Disease · study director
• N/A
  NCT06192563 · A Study to Observe How Pediatric Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions Respond to Dupilumab Treatment

  Sanofi · recruiting · Atopic Dermatitis · study director
• Ph4
  NCT06145373 · A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab

  Sanofi · recruiting · Hemophilia A · study director
• Ph3
  NCT06130566 · A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

  Sanofi · completed · Dermatitis Atopic · study director
• Ph1/Ph2
  NCT06128733 · Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

  Sanofi Pasteur, a Sanofi Company · completed · Meningococcal Immunisation, Healthy Volunteers · study director
• Ph2
  NCT06118099 · Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

  Sanofi · terminated · Hidradenitis · study director
• Ph1
  NCT06114238 · Pharmacokinetic Study to Compare Itepekimab Exposure When Administered With an Autoinjector Versus Prefilled Syringe

  Sanofi · completed · Chronic Obstructive Pulmonary Disease · study director
• Ph1
  NCT06106074 · Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult Participants

  Sanofi · completed · Multiple Sclerosis · study director
• Ph4
  NCT06101095 · A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)

  Sanofi · active not recruiting · Eosinophilic Oesophagitis · study director
• N/A
  NCT06099704 · Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis

  Sanofi · completed · Moderate to Severe Atopic Dermatitis · study director
• N/A
  NCT06087627 · A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine

  Sanofi · active not recruiting · Prurigo Nodularis · study director
• Ph3
  NCT06082037 · A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

  Sanofi · recruiting · Lung Transplant Rejection · study director
• Ph2
  NCT06073093 · A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis

  Sanofi · completed · Rheumatoid Arthritis · study director
• Ph2
  NCT06067425 · Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia

  Sanofi · terminated · Osteochondrodysplasia · study director
• Ph1
  NCT06064539 · Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects

  Sanofi · completed · Multiple Sclerosis · study director
• Ph2
  NCT06033833 · Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study

  Sanofi · terminated · Asthma · study director
• Ph4
  NCT06019728 · A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme

  Sanofi · completed · Fabry's Disease · study director
• N/A
  NCT06018441 · A Study to Evaluate the Quality of Life in Male and Female Adult Participants With Severe Asthma Treated With Dupilumab in a Real-world Setting

  Sanofi · completed · Asthma · study director
• Ph2
  NCT06015308 · A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo

  Sanofi · completed · Dermatitis Atopic · study director
• N/A
  NCT05991323 · Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study

  Sanofi · completed · Prurigo Nodularis · study director
• Ph4
  NCT05983068 · A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis

  Sanofi · active not recruiting · Dermatitis Atopic · study director
• Ph4
  NCT05929651 · Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy

  Sanofi Pasteur, a Sanofi Company · completed · Meningococcal Immunisation, Healthy Volunteers · study director
• Ph1
  NCT05918614 · A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects

  Kadmon, a Sanofi Company · completed · Immune System Disorder (Healthy Volunteer) · study director
• Ph1
  NCT05918588 · A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female Subjects

  Kadmon, a Sanofi Company · completed · Immune System Disorder (Healthy Volunteer) · study director
• Ph1
  NCT05918627 · A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male Subjects

  Kadmon, a Sanofi Company · completed · Immune System Disorder (Healthy Volunteer) · study director
• N/A
  NCT05911763 · A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A

  Sanofi · active not recruiting · Hemophilia A · study director
• N/A
  NCT05908656 · Implementation and Evaluation of a Rare Disease Algorithm to Identify Persons at Risk of Gaucher Disease Using Data From Electronic Health Records (EHRs) in the United States (Project Searchlight)

  Sanofi · completed · Gaucher Disease · study director
• Ph2
  NCT05897424 · Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema

  Sanofi · active not recruiting · Alpha 1-Antitrypsin Deficiency, Emphysema · study director
• Ph1
  NCT05858788 · A Single Ascending Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of SAR441566 in Healthy Adult Japanese Male Participants.

  Sanofi · completed · Rheumatoid Arthritis · study director
• Ph2
  NCT05856331 · Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema

  Sanofi · completed · Alpha 1-Antitrypsin Deficiency, Emphysema · study director
• Ph2
  NCT05849922 · A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa

  Sanofi · completed · Hidradenitis Suppurativa · study director
• Ph1
  NCT05846009 · A First-in-human Single and Repeated Dose Escalation Study of SAR442501 in Healthy Adults Subjects

  Sanofi · completed · Osteochondrodysplasia · study director
• Ph1
  NCT05844735 · A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566

  Sanofi · completed · Rheumatoid Arthritis · study director
• Ph1
  NCT05839626 · A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)

  Sanofi · terminated · Relapsed/Refractory Multiple Myeloma, Amyloid Light-chain Amyloidosis · study director
• Ph1
  NCT05829356 · Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above

  Sanofi Pasteur, a Sanofi Company · completed · Influenza Immunization · study director
• N/A
  NCT05819112 · A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical Illness

  Sanofi · terminated · Venous Thromboembolism · study director
• N/A
  NCT05819125 · Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With Enoxaparin

  Sanofi · terminated · Venous Thromboembolism · study director
• Ph1
  NCT05806567 · A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects

  Kadmon, a Sanofi Company · completed · Immune System Disorder, Healthy Volunteers · study director
• Ph1
  NCT05797701 · A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)

  Sanofi · completed · Amyotrophic Lateral Sclerosis (Healthy Volunteers) · study director
• Ph1
  NCT05797753 · A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)

  Sanofi · completed · Amyotrophic Lateral Sclerosis, Healthy Volunteer · study director
• Ph1
  NCT05795907 · Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants

  Sanofi · completed · Amyotrophic Lateral Sclerosis (Healthy Volunteers) · study director
• Ph3
  NCT05794230 · Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa

  Sanofi Pasteur, a Sanofi Company · completed · Meningococcal Immunisation, Healthy Volunteers · study director
• Ph1
  NCT05796479 · A PK Comparability Study of Two Different Amlitelimab Drug Products in Healthy Participants

  Sanofi · completed · Healthy Volunteers · study director
• Ph2
  NCT05769777 · Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  Sanofi · active not recruiting · Dermatitis Atopic · study director
• Ph4
  NCT05757713 · Teplizumab in Pediatric Stage 2 Type 1 Diabetes

  Sanofi · completed · Diabetes Mellitus, Type 1 · study director
• N/A
  NCT05734521 · Avalglucosidase Alfa Pregnancy Study

  Sanofi · recruiting · Pompe Disease, Pregnancy · study director
• Ph2
  NCT05731128 · A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))

  Sanofi · active not recruiting · Colitis Ulcerative · study director
• Ph2
  NCT05726682 · A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

  Sanofi · withdrawn · Allogenic Stem Cell Transplantation · study director
• Ph4
  NCT05720455 · Study to Assess Safety and Efficacy of Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL Fixed Dose Combination in Indian Male and Female Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above

  Sanofi · completed · Rhinitis Allergic · study director
• Ph1
  NCT05718258 · A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function

  Sanofi · completed · Hepatic Function Abnormal · study director
• Ph1
  NCT05712278 · A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia

  Sanofi · terminated · Acute Myeloid Leukaemia · study director
• Ph2
  NCT05704049 · A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

  Sanofi · active not recruiting · Relapsed/Refractory Multiple Myeloma · study director
• Ph3
  NCT05692154 · A Placebo-controlled Study of 2-day Pre-treatment With Fexofenadine in Seasonal Allergic Rhinitis

  Opella Healthcare Group SAS, a Sanofi Company · completed · Seasonal Allergic Rhinitis · study director
• Ph1/Ph2
  NCT05687279 · Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)

  Sanofi Pasteur, a Sanofi Company · completed · Respiratory Syncytial Virus Infection · study director
• N/A
  NCT05684341 · A Randomized Controlled Trial to Compare the Glycemic Control, With or Without the Connected Solution, of Adult Type 2 Diabetic Participants on Basal Insulin in Taiwan

  Sanofi · completed · Type 2 Diabetes Mellitus · study director
• Ph4
  NCT05680298 · Dupilumab-pediatric Skin Barrier Function and Lipidomics Study in Patients With Atopic Dermatitis in China

  Sanofi · completed · Atopic Dermatitis · study director
• N/A
  NCT05671770 · Study Based on Electronic Health RecOrds to Identify Patients at High-risk of Fabry DiseasE (HOPE Fabry)

  Sanofi · completed · Fabry Disease · study director
• Ph2
  NCT05669989 · International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

  Sanofi · enrolling by invitation · Plasma Cell Myeloma · study director
• Ph3
  NCT05662319 · A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia

  Sanofi · active not recruiting · Hemophilia · study director
• N/A
  NCT05649813 · A Study in Male and Female Adult Participants With Chronic Rhinosinusitis With Nasal Polyps In the Greater Gulf Region

  Sanofi · completed · Chronic Rhinosinusitis With Nasal Polyps · study director
• Ph1/Ph2
  NCT05650554 · Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

  Sanofi Pasteur, a Sanofi Company · completed · Influenza Immunization · study director
• Ph1/Ph2
  NCT05639894 · Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older

  Sanofi Pasteur, a Sanofi Company · completed · Respiratory Syncytial Virus Immunization · study director
• Ph2
  NCT05630547 · A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis

  Sanofi · terminated · Multiple Sclerosis · study director
• N/A
  NCT05628090 · A Study of an Existing Database to Assess the Treatment Persistence to Basal Insulin in Type 2 Diabetes Mellitus Patients in a Structured Patient Education Program in India

  Sanofi · completed · Type 2 Diabetes Mellitus (T2DM) · study director
• Ph1/Ph2
  NCT05624606 · Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

  Sanofi Pasteur, a Sanofi Company · completed · Influenza Immunization · study director
• Ph4
  NCT05624112 · Dupilumab Skin BArrier Function and LIpidomics STudy in Atopic Dermatitis in China

  Sanofi · completed · Atopic Dermatitis, Dermatitis Atopic · study director
• N/A
  NCT05622331 · Burden of Respiratory Syncytial Virus (RSV) in Children in Sweden (BRICS): A Retrospective Study in Sweden

  Sanofi Pasteur, a Sanofi Company · completed · Respiratory Syncytial Virus (RSV) · study director
• N/A
  NCT05607160 · A Study to Observe How Insulin Glargine 300 U/ml is Working and is Tolerated in Elderly Patients ≥75 Years of Age With Type 2 Diabetes

  Sanofi · completed · Type 2 Diabetes Mellitus (T2DM) · study director
• Ph1/Ph2
  NCT05608005 · Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older

  Sanofi Pasteur, a Sanofi Company · completed · Influenza, Healthy Volunteers · study director
• Ph1
  NCT05607173 · A Pharmacokinetic and Tolerability Study of Fexinidazole in a Single Oral Dose in Adult Participants With Mild and Moderate Hepatic Impairment

  Sanofi · completed · Hepatic Function Abnormal · study director
• Ph1/Ph2
  NCT05584670 · A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

  Sanofi · recruiting · Solid Tumor · study director
• N/A
  NCT05568979 · Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022/23

  Sanofi Pasteur, a Sanofi Company · completed · Influenza (Healthy Volunteers) · study director
• Ph2
  NCT05567406 · Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy

  Kadmon, a Sanofi Company · withdrawn · Chronic Graft Versus Host Disease · study director
• Ph1/Ph2
  NCT05553301 · Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

  Sanofi Pasteur, a Sanofi Company · completed · Influenza Immunization · study director
• N/A
  NCT05527964 · A Study to Evaluate the Quality of Life of Male and Female Adult Patients With Severe Refractory Atopic Dermatitis Treated With Dupilumab in Czech Republic

  Sanofi · completed · Atopic Dermatitis · study director
• Ph3
  NCT05513391 · Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years

  Sanofi Pasteur, a Sanofi Company · terminated · Influenza Immunization · study director
• Ph3
  NCT05513053 · Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.

  Sanofi Pasteur, a Sanofi Company · completed · Influenza Immunization · study director
• Ph3
  NCT05468320 · Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura

  Sanofi · completed · Thrombotic Thrombocytopenic Purpura · study director
• Ph1
  NCT05453942 · A Study to Investigate Safety, Tolerability and Clinical Response With SAR441566 Compared With Placebo in Participants With Mild to Moderate Psoriasis

  Sanofi · completed · Psoriasis · study director
• Ph1/Ph2
  NCT05450562 · Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors

  Sanofi · terminated · Neoplasm · study director
• N/A
  NCT05442645 · A Study in Male and Female Adult Patients With Atopic Dermatitis Treated With Dupilumab in Taiwan

  Sanofi · completed · Atopic Dermatitis · study director
• Ph3
  NCT05437510 · Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life

  Sanofi Pasteur, a Sanofi Company · completed · RSV Immunization, Healthy Volunteer · study director
• Ph1
  NCT05429762 · Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors

  Sanofi · terminated · Neoplasm · study director
• Ph1
  NCT05426174 · Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older

  Sanofi Pasteur, a Sanofi Company · completed · Influenza Immunization, Healthy Volunteers · study director
• Ph2
  NCT05421598 · Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma

  Sanofi · completed · Asthma · study director
• Ph3
  NCT05413369 · iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)

  Sanofi · completed · Type 2 Diabetes Mellitus · study director
• Ph3
  NCT05405166 · SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

  Sanofi · active not recruiting · Plasma Cell Myeloma Recurrent · study director
• Ph1
  NCT05366764 · First-in-human Study of SAR443765 in Healthy Participants and in Asthmatic Participants

  Sanofi · completed · Asthma · study director
• N/A
  NCT05359276 · Data Analysis of Adult and Pediatric Participants With Acid Sphingomyelinase Deficiency (ASMD) on Early Access to Olipudase Alfa in France

  Sanofi · completed · Acid Sphingomyelinase Deficiency (ASMD) · study director
• Ph2
  NCT05326412 · Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD

  Sanofi · completed · Chronic Obstructive Pulmonary Disease · study director
• N/A
  NCT05302297 · Comparative Efficacy of Cemiplimab to Historical Standard of Care in France

  Sanofi · completed · Cancer/Squamous Cell Carcinoma of Skin · study director
• Ph1
  NCT05283915 · Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Mild Hepatic Impairment Compared to Participants With Normal Hepatic Function

  Sanofi · completed · Hepatic Function Abnormal · study director
• Ph1
  NCT05282030 · Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants.

  Sanofi · completed · Renal Impairment · study director
• Ph3
  NCT05280548 · A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease

  Sanofi · active not recruiting · Fabry Disease · study director
• Ph2
  NCT05245071 · Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA

  Sanofi · terminated · Non-squamous Non-small Cell Lung Cancer · study director
• Ph1
  NCT05238714 · Excretion Balance, Pharmacokinetics, and Metabolism Following of [14C]-Venglustat Administration in Healthy Male Subjects

  Genzyme, a Sanofi Company · completed · Disorders of Sphingolipid Metabolism, Healthy Volunteers · study director
• Ph2
  NCT05237284 · Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)

  Sanofi · terminated · Amyotrophic Lateral Sclerosis · study director
• N/A
  NCT05235724 · A Study to Assess the Reliability/Feasibility of Using Emerald Touchless Sensor for Scratching and Sleep Quantification in a Subset of Participants From PEDISTAD Study (OBS15333; NCT03687359)

  Sanofi · completed · Dermatitis Atopic · study director
• Ph1
  NCT05231668 · Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)

  Sanofi · terminated · Osteogenesis Imperfecta · study director
• Ph3
  NCT05222906 · Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3

  Sanofi · active not recruiting · Gaucher's Disease Type III · study director
• N/A
  NCT05214326 · A Study to Assess the Disease Control of Moderate to Severe Atopic Dermatitis in Male and Female Participants of Atleast 12 Years Old Receiving Dupilumab Injections in Gulf Countries

  Sanofi · completed · Dermatitis Atopic · study director
• Ph3
  NCT05206773 · A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

  Sanofi · active not recruiting · Fabry Disease · study director
• Ph2
  NCT05179603 · A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]

  Sanofi · terminated · Classic Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma · study director
• N/A
  NCT05178745 · Resection Observatory

  Sanofi · completed · Metastatic Colorectal Cancer, Colorectal Neoplasms · study director
• Ph4
  NCT05164055 · Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)

  Genzyme, a Sanofi Company · active not recruiting · Glycogen Storage Disease Type II · study director
• Ph3
  NCT05137041 · Efficacy and Safety of FIRTECH in Patients With Mild to Moderate Acute Low Back Pain

  Sanofi · completed · Low Back Pain · study director
• Ph4
  NCT05134571 · China Post-marketing Surveillance (PMS) Study of Aldurazyme®

  Genzyme, a Sanofi Company · completed · Mucopolysaccharidosis I · study director
• Ph3
  NCT05132127 · Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan

  Sanofi · completed · Cold Agglutinin Disease · study director
• Ph3
  NCT05132569 · Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis

  Sanofi · terminated · Myasthenia Gravis · study director
• Ph1
  NCT05131373 · Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris

  Sanofi Pasteur, a Sanofi Company · completed · Acne Vulgaris, Acne · study director
• N/A
  NCT05129241 · Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector

  Sanofi · completed · Primary Hypercholesterolaemia and Mixed Dyslipidaemia, Atherosclerotic Cardiovascular Disease · study director
• Ph1
  NCT05126329 · Pharmacokinetics of Amcenestrant in Female Hepatic Impaired Participants as Compared to Participants With Normal Hepatic Function

  Sanofi · terminated · Hepatic Function Abnormal · study director
• Ph4
  NCT05114590 · Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus

  Sanofi · completed · Type 2 Diabetes Mellitus · study director
• Ph2
  NCT05107115 · Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine

  Sanofi · completed · Chronic Spontaneous Urticaria · study director
• Ph2
  NCT05104892 · Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma

  Sanofi · completed · Asthma · study director
• Ph2
  NCT05087628 · PRV-3279-2a Trial in Systemic Lupus

  Provention Bio, a Sanofi Company · terminated · Systemic Lupus Erythematosus · study director
• Ph1/Ph2
  NCT05086315 · First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

  Sanofi · terminated · Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Myelodysplastic Syndromes · study director
• N/A
  NCT05078060 · Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2021/22

  Sanofi Pasteur, a Sanofi Company · completed · Influenza (Healthy Volunteers) · study director
• N/A
  NCT05073783 · A Study to Assess the Safety of Myozyme® and of Aldurazyme® in Male and Female Participants of Any Age Group With Pompe Disease or With Mucopolysaccharidosis Type I (MPS I) in a Home-care Setting

  Sanofi · completed · Pompe Disease, Mucopolysaccharidosis Type I (MPS I) · study director
• N/A
  NCT05070663 · A Study in Male and Female Adolescent Participants With Severe Uncontrolled Asthma Starting Treatment With Dupilumab Injection (Dupixent®)

  Sanofi · completed · Asthma · study director
• Ph2
  NCT05061420 · A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)

  Sanofi · terminated · Squamous Cell Carcinoma of Head and Neck · study director
• Ph4
  NCT05054387 · China Post-marketing Surveillance (PMS) Study of Fabrazyme®

  Genzyme, a Sanofi Company · completed · Fabry Disease · study director
• Ph4
  NCT05050318 · Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

  Sanofi Pasteur, a Sanofi Company · completed · Influenza Immunization, Healthy Volunteers · study director
• N/A
  NCT05040802 · Effectiveness of Adacel Vaccination in Pregnancy at Preventing Pertussis in Infants < 2 Months of Age in the United States

  Sanofi Pasteur, a Sanofi Company · completed · Pertussis (Whooping Cough) · study director
• Ph2
  NCT05039840 · Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus

  Sanofi · active not recruiting · Systemic Lupus Erythematosus · study director
• Ph2
  NCT05011123 · Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia

  Sanofi Pasteur, a Sanofi Company · active not recruiting · Yellow Fever · study director
• Ph4
  NCT04980027 · Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs

  Sanofi · completed · Type 2 Diabetes Mellitus · study director
• Ph2
  NCT04969276 · Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine

  Sanofi Pasteur, a Sanofi Company · completed · Influenza Immunization, Healthy Volunteers · study director
• Ph2
  NCT04942210 · Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA

  Sanofi Pasteur, a Sanofi Company · active not recruiting · Yellow Fever, Healthy Volunteers · study director
• Ph3
  NCT04936685 · Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers

  Sanofi Pasteur, a Sanofi Company · active not recruiting · Meningococcal Immunisation, Healthy Volunteers · study director
• Ph3
  NCT04910776 · Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa

  Sanofi · active not recruiting · Glycogen Storage Disease Type II · study director
• Ph2
  NCT04879628 · Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis

  Sanofi · active not recruiting · Multiple Sclerosis · study director
• N/A
  NCT04877132 · Compassionate Use Program for Olipudase Alfa Enzyme Replacement Therapy for Patients With Chronic Acid Sphingomyelinase Deficiency (ASMD)

  Sanofi · approved for marketing · Sphingomyelin Lipidosis · study director
• N/A
  NCT04848779 · A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)

  Sanofi · active not recruiting · Glycogen Storage Disease Type II · study director
• N/A
  NCT04845958 · A Non-Interventional National Study in Pediatric Patients With Unexplained Enlarged Spleen

  Sanofi · completed · Gaucher Disease, Splenomegaly, Acid SphingoMyelinase Deficiency · study director
• N/A
  NCT04843111 · Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)

  Sanofi Pasteur, a Sanofi Company · recruiting · Meningococcal Infection · study director
• Ph1
  NCT04825223 · Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants

  Sanofi Pasteur, a Sanofi Company · terminated · Meningococcal Immunisation, Healthy Volunteers · study director
• Ph4
  NCT04823130 · Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis

  Sanofi · completed · Dermatitis Atopic · study director
• Ph1
  NCT04802057 · Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088

  Bioverativ, a Sanofi company · terminated · Autoimmune Haemolytic Anaemia · study director
• Ph1/Ph2
  NCT04798027 · Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older

  Sanofi Pasteur, a Sanofi Company · terminated · COVID-19 · study director
• Ph2
  NCT04781816 · Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus

  Sanofi · completed · Cutaneous Lupus Erythematosus · study director
• Ph1
  NCT04770935 · To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)

  Bioverativ, a Sanofi company · completed · Von Willebrand's Disease (VWD) · study director
• Ph2/Ph3
  NCT04762680 · Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older

  Sanofi Pasteur, a Sanofi Company · completed · COVID-19 · study director
• Ph3
  NCT04759131 · Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A

  Bioverativ, a Sanofi company · completed · Hemophilia A · study director
• Ph3
  NCT04751487 · Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

  Sanofi · completed · Chronic Obstructive Pulmonary Disease · study director
• Ph1
  NCT04748926 · Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants

  Principia Biopharma, a Sanofi Company · completed · Healthy Volunteers · study director
• Ph4
  NCT04718870 · Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis

  Sanofi · completed · Dermatitis Atopic · study director
• Ph1/Ph2
  NCT04717375 · Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

  Sanofi · terminated · Cancer, Neoplasm · study director
• Ph3
  NCT04705051 · Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat

  Sanofi · terminated · Congenital Cystic Kidney Disease · study director
• Ph3
  NCT04701983 · Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

  Sanofi · completed · Chronic Obstructive Pulmonary Disease · study director
• Ph3
  NCT04684524 · Dupilumab in Allergic Fungal Rhinosinusitis (AFRS)

  Sanofi · completed · Allergic Fungal Rhinosinusitis · study director
• Ph3
  NCT04681729 · Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)

  Sanofi · completed · Cold Urticaria · study director
• Ph2
  NCT04678856 · Dupilumab in CRSsNP

  Sanofi · completed · Chronic Rhinosinusitis Without Nasal Polyps, Sinusitis, Chronic Sinusitis · study director
• Ph3
  NCT04678882 · Dupilumab in Japanese Patients With Atopic Dermatitis

  Sanofi · completed · Atopic Dermatitis · study director
• Ph4
  NCT04676373 · Study to Evaluate Efficacy and Safety in Chinese Patients With Late Onset Pompe Disease With Alglucosidase Alfa Treatmen

  Genzyme, a Sanofi Company · completed · Pompe's Disease · study director
• Ph2
  NCT04669600 · A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)

  Bioverativ, a Sanofi company · completed · Immune Thrombocytopenia (ITP) · study director
• Ph3
  NCT04669041 · A Study to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia Not Adequately Controlled on Statin Therapy

  Sanofi · completed · Hypercholesterolemia · study director
• Ph2
  NCT04661033 · Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)

  Sanofi · terminated · Warm Autoimmune Hemolytic Anemia (wAIHA) · study director
• Ph2
  NCT04659603 · Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors

  Sanofi · terminated · Breast Cancer Metastatic, Pancreatic Carcinoma Metastatic · study director
• Ph2
  NCT04658472 · Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  Bioverativ, a Sanofi company · completed · Chronic Inflammatory Demyelinating Polyradiculoneuropathy · study director
• Ph4
  NCT04656600 · Study to Evaluate Efficacy and Safety of Imiglucerase Treatment in Chinese Patients With Gaucher Disease Type Ⅲ

  Sanofi · completed · Gaucher's Disease · study director
• Ph3
  NCT04644575 · Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A

  Bioverativ, a Sanofi company · active not recruiting · Hemophilia A · study director
• Ph1/Ph2
  NCT04643002 · Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

  Sanofi · recruiting · Plasma Cell Myeloma Refractory · study director
• N/A
  NCT04598893 · Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)

  Provention Bio, a Sanofi Company · active not recruiting · Diabetes Mellitus, Type 1 · study director
• Ph3
  NCT04594551 · Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in Thaïland

  Sanofi Pasteur, a Sanofi Company · completed · Rabies (Healthy Volunteers) · study director
• Ph2
  NCT04583618 · Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.

  Sanofi · completed · Pneumococcal Immunization · study director
• Ph2
  NCT04572841 · Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)

  Sanofi · completed · Sjögren's Syndrome, Sjogren's Syndrome · study director
• N/A
  NCT04550962 · Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)

  Sanofi · completed · Asthma · study director
• Ph4
  NCT04551677 · Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

  Sanofi Pasteur, a Sanofi Company · completed · Influenza Immunization, Healthy Volunteers · study director
• Ph3
  NCT04544267 · Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age

  Sanofi Pasteur, a Sanofi Company · terminated · Influenza · study director
• Ph3
  NCT04537234 · Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older

  Sanofi Pasteur, a Sanofi Company · completed · Influenza (Healthy Volunteers) · study director
• Ph1/Ph2
  NCT04537208 · Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older

  Sanofi Pasteur, a Sanofi Company · completed · COVID-19 (Healthy Volunteers) · study director
• Ph2
  NCT04524689 · Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC

  Sanofi · terminated · Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) · study director
• Ph1
  NCT04521738 · First-in-human Study to Assess Safety and Tolerability of a Single Subcutaneous Dose of SAR441255 in Lean to Overweight Subjects

  Sanofi · completed · Overweight, Healthy Subjects · study director

Grants

NIH projects from RePORTER, fetched 2026-11-12 12:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.